Almirall SA · BME:ALM
Almirall SA — Fifth Annual Piper Jaffray Europe Conference 2010
13 slides from Almirall SA's conference presentation, Jun 22, 2010
Slide 1: Fifth Annual Piper Jaffray Europe Conference
Fifth Annual Piper Jaffray Europe Conference London, 22nd June 2010
Slide 2: Disclaimer
Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptio
Slide 3: A fully integrated company with global reach
A fully integrated company with global reach Founded in 1943. IPO in 2007 3 11 Affiliates in R&D Centres in Europe and Latin Spain and Germany America Our products are Manufacturing present in the five Plants in Spain and continents (more Germany than 70 countries) 3
Slide 4: Our business model
Our business model A successful combination of R&D and corporate development 4 2009 Sales Direct sales by Almirall through 11 affiliates € 925 Mill. Almirall has been a successful in-licensor Europe Linaclotide Ironwood Europe Sativex® GW Pharma (ex-UK) 45% 55% Proprietary Other Spain Sitagliptin MS
Slide 5: Strategic focus
Strategic focus Consistency and positive evolution since IPO (€ rounded million) 2007 2008 2009 International 271,2 368,8 389,5 expansion International sales International sales International sales % of total sales 34% 41% 42% Leadership 521,3 534,0 536,0 in Spain Spanish sales Spanish sales Spanish
Slide 6: Summary – Q1 2010 Financial Results
Summary – Q1 2010 Financial Results • Sales on track (-1,0%), Normalized Net Income ahead of guidance (+3,0%). • Cost discipline and savings a priority for 2010 (SG&A : -12,2% in Q1’10). • Net Debt reduced to x 0,09 EBITDA 2009. • Recurrent Free Cash Flow generation. YTD YTD € rounded m illion % Var
Slide 7: Strong track record in nourishing the base business
Strong track record in nourishing the base business 2005 2006 2007 2008 2009 2010 Hermal OD LABA GmbH US Sativex® Toctino® * Europe Tesavel® (alitretinoin) (ex-UK) (sitagliptin) Spain Linaclotide Europe Sofotec Astucor® Silodosin (amlodipine + Eklira ® Spain atorvastatin) US Spain Pantopan® Divestme
Slide 8: A pipeline with significant upside (I)
Respiratory A pipeline with significant upside (I) Auto-immune (the right end of each bar represents status of development as of May 13th 2010) Expected filing Preclinical Ph I Ph II Ph III Registration date Eklira® (anti- (aclidinium COPD COPD 2011 bromide) muscarinic) (anti- AB + Formoterol muscar
Slide 9: A pipeline with significant upside (II)
A pipeline with significant upside (II) Dermatology Gastrointestinal (the right end of each bar represents status of development as of May 13th 2010) Expected filing Preclinical Ph I Ph II Ph III Registration date Skin Skin inflammation inflammation (e.g. (e.g. eczema, eczema, psoriasis) psoriasis)
Slide 10: Significant pipeline newsflow during 2010
Significant pipeline newsflow during 2010 Q2’10 Q2’10 Q3’10 Q3’10 Q4’10 Q4’10 2011 2011 Eklira® (AB) and Genuair® Update at ATS LAS100977 (OD LABA) AB + formoterol Phase IIa details at ATS Phase IIb results R&D R&D Eklira® (AB) Phase III BID results Linaclotide Topline data from two Phase III trials
Slide 11: Almirall as investment case
Almirall as investment case Solid fundamentals focused on long term value creation Combining a well-established business … …with significant upside from pipeline Broadest and deepest pipeline in Branded, patented balanced portfolio. company history. Presence in major Europe. Eklira® franchis
Slide 12: Outlook 2010
Outlook 2010 Financial Outlook 2010 • Sales and normalized net income (excluding extraordinary items) expected to decline by mid single digits in 2010 compared to 2009. • Ongoing cost containment efforts (except for R&D). Corporate Development: partnering and pipeline • Partnering key pipeline produ
Slide 13: Almirall – Solutions with you in mind
Zé . (% Almirall Solutions with you in mind
Almirall — Fifth Annual Piper Jaffray Europe Conference 2010 on 6ix